Long function evolution of the montelukast and placebo group.

Patients were subdivided in stable (110%-90% FEV1 compared to the FEV1 at the moment of CLAD diagnosis), increase (>110%) and decrease (<90%), no difference was observed (p = 0.16). No result = no result could be obtained in 2 patients in the placebo group and 3 patients in the montelukast groups due to mortality, concurrent infection, missed appointment. MLK = montelukast.

患者按慢性肺移植功能障碍（Chronic Lung Allograft Dysfunction，CLAD）确诊时的一秒用力呼气容积（Forced Expiratory Volume in 1 second，FEV1）相对占比被分为三组：稳定组（FEV1为CLAD确诊时FEV1的90%~110%）、FEV1升高组（占比>110%）与FEV1降低组（占比<90%），三组间未观察到显著统计学差异（p=0.16）。无有效结果指：安慰剂组与孟鲁司特（montelukast）组分别有2例、3例患者因死亡、合并感染或失约未获得检测结果。MLK即孟鲁司特。